CA3068357C - New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it - Google Patents

New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it Download PDF

Info

Publication number
CA3068357C
CA3068357C CA3068357A CA3068357A CA3068357C CA 3068357 C CA3068357 C CA 3068357C CA 3068357 A CA3068357 A CA 3068357A CA 3068357 A CA3068357 A CA 3068357A CA 3068357 C CA3068357 C CA 3068357C
Authority
CA
Canada
Prior art keywords
cancer
tumors
lymphoma
leukemia
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3068357A
Other languages
English (en)
French (fr)
Other versions
CA3068357A1 (en
Inventor
Massimo Zampieri
Marina Caldarelli
Ilaria Candiani
Matteo D'anello
Germano D'arasmo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Publication of CA3068357A1 publication Critical patent/CA3068357A1/en
Application granted granted Critical
Publication of CA3068357C publication Critical patent/CA3068357C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3068357A 2017-06-29 2018-06-28 New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it Active CA3068357C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305826 2017-06-29
EP17305826.4 2017-06-29
PCT/EP2018/067394 WO2019002454A1 (en) 2017-06-29 2018-06-28 NOVEL N- (2,6-DIETHYLPHENYL) -8 - ({4- [4- (DIMETHYLAMINO) PIPERIDIN-1-YL] -2-METHOXYPHENYL} AMINO) -1-METHYL-4,5-DIHYDRO-1H SALT -PYRAZOLO [4,3-H] QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION AND FORMULATIONS CONTAINING THE SAME

Publications (2)

Publication Number Publication Date
CA3068357A1 CA3068357A1 (en) 2019-01-03
CA3068357C true CA3068357C (en) 2022-04-19

Family

ID=59313166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068357A Active CA3068357C (en) 2017-06-29 2018-06-28 New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it

Country Status (19)

Country Link
US (3) US11160806B2 (https=)
EP (1) EP3645535B1 (https=)
JP (1) JP7141416B2 (https=)
KR (1) KR102609333B1 (https=)
CN (1) CN110896636B (https=)
AR (1) AR112040A1 (https=)
AU (1) AU2018293729B9 (https=)
CA (1) CA3068357C (https=)
CL (1) CL2019003848A1 (https=)
EA (1) EA039764B1 (https=)
ES (1) ES2900048T3 (https=)
IL (1) IL271628B2 (https=)
MA (1) MA49498A (https=)
PL (1) PL3645535T3 (https=)
PY (1) PY1850855A (https=)
SG (1) SG11201912651WA (https=)
TW (1) TWI750393B (https=)
UY (1) UY37778A (https=)
WO (1) WO2019002454A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002962A1 (en) 2023-06-30 2025-01-02 Nerviano Medical Sciences S.R.L. Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma
WO2025021587A1 (en) 2023-07-21 2025-01-30 Nerviano Medical Sciences S.R.L. Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010013843A (es) 2008-06-26 2011-01-21 Nerviano Medical Sciences Srl Pirazolo-quinazolinas.

Also Published As

Publication number Publication date
EA202090115A1 (ru) 2020-05-25
EA039764B1 (ru) 2022-03-11
US11160806B2 (en) 2021-11-02
JP2020525477A (ja) 2020-08-27
WO2019002454A1 (en) 2019-01-03
EP3645535B1 (en) 2021-09-08
PL3645535T3 (pl) 2022-03-21
JP7141416B2 (ja) 2022-09-22
CL2019003848A1 (es) 2020-07-10
KR20200020905A (ko) 2020-02-26
CN110896636A (zh) 2020-03-20
EP3645535A1 (en) 2020-05-06
US20200246339A1 (en) 2020-08-06
PY1850855A (es) 2019-04-01
AU2018293729B2 (en) 2022-03-10
AR112040A1 (es) 2019-09-11
CA3068357A1 (en) 2019-01-03
IL271628A (en) 2020-02-27
CN110896636B (zh) 2022-07-19
ES2900048T3 (es) 2022-03-15
UY37778A (es) 2019-01-31
KR102609333B1 (ko) 2023-12-01
TWI750393B (zh) 2021-12-21
MA49498A (fr) 2021-05-26
IL271628B2 (en) 2023-07-01
BR112019027924A2 (pt) 2020-08-18
US20240350501A1 (en) 2024-10-24
AU2018293729B9 (en) 2022-07-14
AU2018293729A1 (en) 2020-01-23
TW201904971A (zh) 2019-02-01
IL271628B1 (en) 2023-03-01
SG11201912651WA (en) 2020-01-30
US20220016122A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
JP7240784B2 (ja) ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物
EP3091020B1 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CN111148745A (zh) Fgfr抑制剂的结晶形式及其制备方法
US20240350501A1 (en) SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
CN104066735B (zh) 作为akt激酶抑制剂的取代的咪唑并吡嗪
TW202540122A (zh) Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法
CZ139097A3 (cs) 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi
CN110167941B (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
JP2013530250A (ja) 二環式ピリミジン化合物
WO2020077944A1 (zh) 嘌呤系列衍生物及其制备方法和用途
CN106467540B (zh) 蝶啶酮衍生物作为flt3抑制剂的应用
CN104066736A (zh) 作为akt激酶抑制剂的取代的吡唑并嘧啶
WO2024255837A1 (zh) 一种enpp1抑制剂的晶型
HK40022862A (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40022862B (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
BR112019027924B1 (pt) Fosfato de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2- metoxifenil}amino)-1-metil-4,5-di-hidro-1h-pirazolo[4,3-h]quinazolina-3- carboxamida, processo para a sua obtenção, composição farmacêutica, combinação e seus usos
HK1231052A1 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
AU2013204831A1 (en) Hydrochloride salt of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191223

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620